The $2.5 m of Receivables mentioned in the 4 c will show up as Revenue in the FY Financials and no mention of the R&D rebate for FY22 in the 4th Qtr 4 c. Something to look out for in the FY results ( AUD 700 k ??) If not shown, could boost the FY23 1st Q receipts, lifting what has historically been the lowest QTR for customer receipts, with the Company repeatedly blaming the USA summer holiday period.
Keenly await some numbers on the new verticals. This too could smooth out the receipts numbers going forward. Been patient with my investment here, but FY 2023 must deliver on the potential and demonstrate operational leverage or I will be reviewing the size of my holding.
Rokewa
Ann: Enterprise Sales & ACV Update, page-64
-
- There are more pages in this discussion • 10 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Add 3DP (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
4.1¢ |
Change
0.001(2.50%) |
Mkt cap ! $33.00M | |||
| Open | High | Low | Value | Volume |
| 4.0¢ | 4.1¢ | 3.9¢ | $14.82K | 369.7K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 3 | 162522 | 4.0¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 4.1¢ | 1892138 | 2 |
View Market Depth
| Last trade - 15.59pm 13/11/2024 (20 minute delay) ? |
| 3DP (ASX) Chart |